Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study

da Silva, 2014, Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis, World J Gastroenterol, 20, 9458, 10.3748/wjg.v20.i28.9458 Langholz, 1994, Course of ulcerative colitis: analysis of changes in disease activity over years, Gastroenterology, 107, 3, 10.1016/0016-5085(94)90054-X Benchimol, 2011, Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends, Inflamm Bowel Dis, 17, 423, 10.1002/ibd.21349 Turner, 2012, Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines, J Pediatr Gastroenterol Nutr, 55, 340, 10.1097/MPG.0b013e3182662233 Jakobsen, 2011, Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease – a population-based study, Aliment Pharmacol Ther, 34, 1217, 10.1111/j.1365-2036.2011.04857.x Van Limbergen, 2008, Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease, Gastroenterology, 135, 1114, 10.1053/j.gastro.2008.06.081 Turner, 2008, Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy, Gut, 57, 331, 10.1136/gut.2007.136481 Dinesen, 2010, The pattern and outcome of acute severe colitis, J Crohns Colitis, 4, 431, 10.1016/j.crohns.2010.02.001 Gower-Rousseau, 2009, The natural history of pediatric ulcerative colitis: a population-based cohort study, Am J Gastroenterol, 104, 2080, 10.1038/ajg.2009.177 Turner, 2018, Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition, J Pediatr Gastroenterol Nutr, 67, 257, 10.1097/MPG.0000000000002035 Harbord, 2017, Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management, J Crohns Colitis, 11, 769, 10.1093/ecco-jcc/jjx009 Rubin, 2019, ACG clinical guideline: ulcerative colitis in adults, Am J Gastroenterol, 114, 384, 10.14309/ajg.0000000000000152 Fell, 2016, Management of ulcerative colitis, Arch Dis Child, 101, 469, 10.1136/archdischild-2014-307218 Turner, 2017, Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: a randomised controlled trial, J Crohns Colitis, 11, 527 D’Haens, 2012, Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis, Am J Gastroenterol, 107, 1064, 10.1038/ajg.2012.103 Kane, 2012, Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis, Inflamm Bowel Dis, 18, 1026, 10.1002/ibd.21841 Sandborn, 2007, MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials, Aliment Pharmacol Ther, 26, 205, 10.1111/j.1365-2036.2007.03361.x Da Silva Sanchez, 2015, Pooled safety analysis of long-term, once-daily multimatrix mesalazine use, J Crohns Colitis, 9 Flood, 2017, Development of the pediatric daily ulcerative colitis signs and symptoms scale (DUCS): qualitative research findings, BMC Res Notes, 10, 491, 10.1186/s13104-017-2814-3 Turner, 2007, Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study, Gastroenterology, 133, 423, 10.1053/j.gastro.2007.05.029 Turner, 2009, Appraisal of the pediatric ulcerative colitis activity index (PUCAI), Inflamm Bowel Dis, 15, 1218, 10.1002/ibd.20867 Cuffari, 2016, Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis, Drug Des Devel Ther, 10, 593, 10.2147/DDDT.S95316 2021 Kane, 2006, Systematic review: adherence issues in the treatment of ulcerative colitis, Aliment Pharmacol Ther, 23, 577, 10.1111/j.1365-2036.2006.02809.x Kamm, 2008, Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis, Gut, 57, 893, 10.1136/gut.2007.138248 Winter, 2014, High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis, J Pediatr Gastroenterol Nutr, 59, 767, 10.1097/MPG.0000000000000530